Kotak Alternate Asset Managers
VC Fund
Mumbai, India
Kotak Alternate Asset Managers is a VC fund in Mumbai focused on Health Care and Biotechnology. Kotak Investment Advisors focuses exclusively on managing the alternate assets business of the Kotak Mahindra Group.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 79%
- Fund size:
- $26M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Kotak Alternate Asset Managers invests in
Stages Kotak Alternate Asset Managers invests in
Countries Kotak Alternate Asset Managers invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $4M–$12M
- Debt Financing
- $3.5M–$134M
- Private Equity
- $7.3M–$142M
Investment Focus
Industry
- Health Care 13 (33%)
- Biotechnology 7 (18%)
- Manufacturing 6 (15%)
- Medical 5 (13%)
- Health Diagnostics 5 (13%)
Stage
- Private Equity 11 (28%)
- Series A 7 (18%)
- Debt Financing 7 (18%)
- Series B 3 (8%)
- Post-IPO Debt 3 (8%)
Country
- India 30 (77%)
- United States 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eshwar Karra
CEO
|
CEO | Total investments: 7 | Find email | |
Rajeev Saptarshi
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
Ramakrishna K. V.
Team Member
|
Team Member | Total investments: 0 | Find email | |
Alroy Lobo
CEO
|
CEO | Total investments: 0 | Find email | |
Lakshmi Iyer
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vishwa Samudra Group is a diversified multinational business conglomerate focused on integrating ecology, economic growth, and social responsibility through sustainable infrastructure, energy, real estate, and technology-driven development initiatives. | $37.7M / Debt Financing / Jun 02, 2026 | ||
| Cellogen Therapeutics is a biotech company that is currently working on developing revolutionary cell therapy-based solutions. It treats a variety of hematological malignancies, solid tumors, and hemoglobinopathies using modern cellular engineering tools and gene therapy. | $2.1M / Seed / May 18, 2026 | ||
| Lloyds Metals And Energy is an iron manufacturing company. It expanded by installing a waste heat recovery based 30 mw co generation captive power plant using waste heat from kiln off gasses generated from the kilns while manufacturing sponge iron. | $78.3M / Post-IPO Debt / May 14, 2026 | ||
| Zeroharm is a wellness products company that supplies nutritional supplement products. | $7.2M / Series A / Feb 18, 2026 | ||
| Avammune Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Avammune is developing a multimodal approach to modulate the STING pathway to treat cancer. Their multimodal approach employs a combination of engineered viruses and small molecules. | $12M / Series A / May 07, 2025 | ||
| Ace Designers is the flagship company of the Ace Micromatic Group. The company was started in 1979 as a design consultancy firm by three CMTI engineers. Initially, the team created product ideas for a variety of machine tools, including specialized equipment. Ace entered the manufacturing sector in 1982 with a line of special purpose importsubstitution machines for the internal combustion engine valve industry. | $141.9M / Private Equity / Apr 30, 2025 | ||
| Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Our current program is on the depigmenting disorder, Vitiligo. | $5M / Series A / Sep 25, 2024 | ||
| Nutrabay is a D2C multi-brand nutrition store that provides an online platform to sell nutritional supplements. Its products include proteins, whey proteins, mass gainers, amino acids, creatine, multivitamins, fish oil, herbs, and many more. | $5M / Series A / Sep 02, 2024 | ||
|
Matrix Pharma
|
The purpose of the pharmaceutical matrix industry is to create a platform to build a robust API business that can support organic and inorganic growth. | $172.9M / Venture - Series Unknown / Jun 11, 2024 | |
|
Matrix Pharma
|
The purpose of the pharmaceutical matrix industry is to create a platform to build a robust API business that can support organic and inorganic growth. | Debt Financing / Jun 11, 2024 | |
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Kotak Alternate Asset Managers invest in?
Kotak Alternate Asset Managers invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Private Equity and Series A stage. Most of the 39 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Kotak Alternate Asset Managers invest in?
Kotak Alternate Asset Managers typically joins rounds of $4M–$12M at Series A, $3.5M–$134M at Debt Financing and $7.3M–$142M at Private Equity. These are whole funding-round sizes, not Kotak Alternate Asset Managers's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Kotak Alternate Asset Managers took part in.
How do I contact Kotak Alternate Asset Managers?
Public channels for Kotak Alternate Asset Managers include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kotak Alternate Asset Managers?
The team at Kotak Alternate Asset Managers includes Eshwar Karra (CEO), Rajeev Saptarshi (Chief Operating Officer) and Ramakrishna K. V. (Team Member), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
